The Astute Board of Directors consists of individuals with proven leadership skills
which allow for successful innovation and commercialization.
Paul H. McPherson, PhD | Chief Scientific Officer, Co-Founder
James C. Blair | Board of Directors
Kim D. Blickenstaff | Board of Directors
Kenneth F. Buechler, Ph.D. | Board of Directors
Frederick J. Dotzler | Board of Directors
David L. Douglass | Board of Directors
Jim Scopa, JD, MBA | Board of Directors
Mr. Hibberd has more than 20 years’ experience as a leader in business strategy and corporate development. Prior to the founding of Astute Medical in 2007, Mr. Hibberd spent 10 years at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations for $1.7 billion. As Senior Vice-President of Corporate Development at Biosite, Mr. Hibberd was co-responsible for the identification and pursuit of strategic business opportunities, including technology acquisitions, partnerships and alliances.
Before joining Biosite, Mr. Hibberd was manager at the Boston Consulting Group (BCG) and was responsible for leading international consultants and client case teams in developing and implementing value-creating strategies for businesses in a variety of industry sectors. Prior to that he held consulting positions at various companies and also was a Development Engineer for Albright & Wilson Americas from 1987 to 1990.
Mr. Hibberd received a Bachelor’s Degree in Chemical Engineering from the University of Toronto, Canada and earned a Master’s in Business Administration from the University of Western Ontario, Canada.
Dr. McPherson has over 25 years’ experience in research and development. He has over 25 issued and pending U.S. patents in areas ranging from immunoassay readers to novel biomarker content in a variety of disease areas.
Prior to co-founding Astute Medical in 2007, Dr. McPherson was vice president of research and development at Biosite Inc., a leading diagnostics company acquired by Inverness Medical Innovations for $1.7 billion. During his 14-year tenure at Biosite, Dr. McPherson led the company’s 85-person research and development team in its hunt for new biomarkers for disease. The team successfully developed and launched eight FDA-cleared products, which included novel diagnostics for congestive heart failure and stroke. He played a key role in the development and commercialization of Biosite’s Triage® Meter Platform and the Triage® family of point-of-care immunoassay products.
Dr. McPherson was a post-graduate research physicist at the University of California, San Diego, where he conducted and published research on the biophysics of photosynthesis.
He earned a doctorate in physics (biophysics) from the University of California, San Diego and a bachelor’s in physics from the University of California, Santa Cruz.